Alysis performed to assess the impact of LFU on the mortality

Alysis performed to assess the impact of LFU on the mortality analysis showed the factors associated with mortality remained largely the same. In contrast to findings in this study a similar analysis performed on data from a cohort in Europe and North America found that a diagnosis of non-Hodgkins lymphoma and progressive multifocal leukoencephalopathy were most strongly associated with mortality after ART initiation in resource-rich settings [35]. The overall mortality in this study was 3.6 over a median follow-up of 43 months, which was lower than our study and the median CD4 count at initiation of therapy was higher. This is likely to reflect differences in the incidence of endemic pathogens [36] as well as poorer access to both diagnostics and therapeutics in resource limited settings. This study has several limitations. The diagnosis of HIV associated conditions was at the discretion of treating clinicians, rather 16574785 than according to pre-specified protocols. MSF has standardized guidelines for diagnosis and treatment of opportunistic infections, but it is likely that variable approaches to diagnosis and treatment were taken. Some conditions such as cytomegalovirus infection are difficult to diagnose and treat in RLS and thus were uncommonly diagnosed. Treatment of conditions would have also varied between sites depending on the availability and ability to administer some therapeutic agents such as amphotericin. Nevertheless we believe the limitations inImpact of HIV-Associated Conditionsthe provision of treatment at some sites would be representative of difficulties seen in many other RLS. Also low body weight, which has often been associated with mortality in people with HIV [3,4], was associated with mortality in the univariate analysis, but had to be excluded from the multivariate analysis for statistical reasons. It is possible this was due to a different association between weight and mortality in Asia compared with Africa. The lack of pre-ART data precluded comparison of mortality rates before and after initiation of ART, and an assessment of associations of specific WHO conditions diagnosed pre-ART with mortality on ART. Finally, the Asian data included in our study was derived from programs mainly operating in Myanmar, limiting the generalisability of our findings to other settings in this region, particularly middle-income countries. Data from a program in Moldova was included to increase power for the primary analysis however there were PZ-51 cost insufficient ��-Sitosterol ��-D-glucoside biological activity patients from Moldova to allow a meaningful comparison of Eastern European patients with those from Africa or Asia. In conclusion this study has demonstrated that patients commencing ART in RLS are exposed to a high risk of mortality in the early ART period and that specific WHO stage3 and 4 conditions contribute significantly to this risk. Understanding the relative contribution of these conditions to mortality during early ART will assist with initiatives to reduce excess mortality during this period, including prioritization of resources for diagnostics, treatment and research. Strategies to reduce mortality during early ART are needed, including earlier HIV diagnosis and linkage to care, ongoing commitment to ART access and improved screening and treatment of opportunistic infections.AcknowledgmentsWe would like to acknowledge the MSF staff, patients and families.Author ContributionsConceived and designed the experiments: DPO JHE LS EA. Analyzed the data: CSM AJC TS JG. Wro.Alysis performed to assess the impact of LFU on the mortality analysis showed the factors associated with mortality remained largely the same. In contrast to findings in this study a similar analysis performed on data from a cohort in Europe and North America found that a diagnosis of non-Hodgkins lymphoma and progressive multifocal leukoencephalopathy were most strongly associated with mortality after ART initiation in resource-rich settings [35]. The overall mortality in this study was 3.6 over a median follow-up of 43 months, which was lower than our study and the median CD4 count at initiation of therapy was higher. This is likely to reflect differences in the incidence of endemic pathogens [36] as well as poorer access to both diagnostics and therapeutics in resource limited settings. This study has several limitations. The diagnosis of HIV associated conditions was at the discretion of treating clinicians, rather 16574785 than according to pre-specified protocols. MSF has standardized guidelines for diagnosis and treatment of opportunistic infections, but it is likely that variable approaches to diagnosis and treatment were taken. Some conditions such as cytomegalovirus infection are difficult to diagnose and treat in RLS and thus were uncommonly diagnosed. Treatment of conditions would have also varied between sites depending on the availability and ability to administer some therapeutic agents such as amphotericin. Nevertheless we believe the limitations inImpact of HIV-Associated Conditionsthe provision of treatment at some sites would be representative of difficulties seen in many other RLS. Also low body weight, which has often been associated with mortality in people with HIV [3,4], was associated with mortality in the univariate analysis, but had to be excluded from the multivariate analysis for statistical reasons. It is possible this was due to a different association between weight and mortality in Asia compared with Africa. The lack of pre-ART data precluded comparison of mortality rates before and after initiation of ART, and an assessment of associations of specific WHO conditions diagnosed pre-ART with mortality on ART. Finally, the Asian data included in our study was derived from programs mainly operating in Myanmar, limiting the generalisability of our findings to other settings in this region, particularly middle-income countries. Data from a program in Moldova was included to increase power for the primary analysis however there were insufficient patients from Moldova to allow a meaningful comparison of Eastern European patients with those from Africa or Asia. In conclusion this study has demonstrated that patients commencing ART in RLS are exposed to a high risk of mortality in the early ART period and that specific WHO stage3 and 4 conditions contribute significantly to this risk. Understanding the relative contribution of these conditions to mortality during early ART will assist with initiatives to reduce excess mortality during this period, including prioritization of resources for diagnostics, treatment and research. Strategies to reduce mortality during early ART are needed, including earlier HIV diagnosis and linkage to care, ongoing commitment to ART access and improved screening and treatment of opportunistic infections.AcknowledgmentsWe would like to acknowledge the MSF staff, patients and families.Author ContributionsConceived and designed the experiments: DPO JHE LS EA. Analyzed the data: CSM AJC TS JG. Wro.